Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells

被引:6
|
作者
Klaihmon, Phatchanat [1 ]
Luanpitpong, Sudjit [1 ,2 ]
Kang, Xing [1 ]
Issaragrisil, Surapol [1 ,3 ,4 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Blood Prod & Cellular Immunotherapy Res Grp, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Fac Med, Siriraj Hosp 2, Dept Med,Siriraj Hosp,Div Hematol, Bangkok 10700, Thailand
[4] Wattanosoth Canc Hosp, BDMS Ctr Excellence Hematol, Bangkok, Thailand
关键词
Induced pluripotent stem cells; Natural killer cells; Chimeric antigen receptor; CAR; TIM3; Acute myelogenous leukemia; Immunotherapy; T-CELLS; TRANSPLANTATION; CANCER; TIM-3; EXPRESSION; HIERARCHY; EXPANSION;
D O I
10.1186/s12935-023-03153-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAcute myeloid leukemia (AML) is a clonal malignant disorder which originates from a small number of leukemia-initiating cells or leukemic stem cells (LSCs)-the subpopulation that is also the root cause of relapsed/refractory AML. Chimeric antigen receptor (CAR)-T cell therapy has proved successful at combating certain hematologic malignancies, but has several hurdles that limit its widespread applications. CAR-natural killer (NK) cells do not carry the risk of inducing graft-versus-host disease (GvHD) frequently associated with allogeneic T cells, thereby overcoming time-consuming, autologous cell manufacturing, and have relatively safer clinical profiles than CAR-T cells. The present study aimed to generate anti-TIM3 CAR-NK cells targeting LSCs from a clonal master induced pluripotent stem cells engineered with the third-generation anti-TIM3 CAR.MethodsA clonal master umbilical cord blood NK-derived induced pluripotent stem cell (iPSC) line, MUSIi013-A, was used as a starting cells for engineering of an anti-TIM3 CAR harboring TIM3 scFv fragment (clone TSR-022), CD28, 4-1BB, and CD3 zeta signaling (CAR-TIM3). The established CAR-TIM3 iPSCs were further differentiated under serum- and feeder-free conditions into functional CAR-TIM3 NK cells and tested for its anti-tumor activity against various TIM3-positive AML cells.ResultsWe successfully established a single-cell clone of CAR-TIM3 iPSCs, as validated by genomic DNA sequencing as well as antibody and antigen-specific detection. We performed thorough iPSC characterization to confirm its retained pluripotency and differentiation capacity. The established CAR-TIM3 iPSCs can be differentiated into CAR-TIM3 NK-like cells, which were further proven to have enhanced anti-tumor activity against TIM3-positive AML cells with minimal effect on TIM3-negative cells when compared with wild-type (WT) NK-like cells from parental iPSCs.ConclusionsiPSCs engineered with CARs, including the established single-cell clone CAR-TIM3 iPSCs herein, are potential alternative cell source for generating off-the-shelf CAR-NK cells as well as other CAR-immune cells. The feasibility of differentiation of functional CAR-TIM3 NK cells under serum- and feeder-free conditions support that Good Manufacturing Practice (GMP)-compliant protocols can be further established for future clinical applications.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)
    Peng, Xiaobo
    Chen, Ling
    Chen, Longpei
    Wang, Bin
    Wang, Yiran
    Zhan, Xianbao
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [22] Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
    Imeri, Jusuf
    Marcoux, Paul
    Huyghe, Matthias
    Desterke, Christophe
    Fantacini, Daianne Maciely Carvalho
    Griscelli, Frank
    Covas, Dimas T.
    de Souza, Lucas Eduardo Botelho
    Griscelli, Annelise Bennaceur
    Turhan, Ali G.
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [23] Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
    Yilmaz, Ahmet
    Cui, Hanwei
    Caligiuri, Michael A.
    Yu, Jianhua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [24] Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
    Ahmet Yilmaz
    Hanwei Cui
    Michael A. Caligiuri
    Jianhua Yu
    Journal of Hematology & Oncology, 13
  • [25] GENETICALLY ENGINEERED INDUCED PLURIPOTENT STEM CELLS (IPSC) FOR THE EFFICIENT GENERATION OF HYPOIMMUNOGENEIC CHIMERIC ANTIGEN RECEPTOR (CAR)-ENGINEERED T CELLS
    Nianias, Alexandros
    Katsarou, Afroditi
    Prins, Henk-Jan
    Shahrabi, Aida
    van Velzen, Cindy
    Groen, Richard
    Mutis, Tuna
    Themeli, Maria
    EXPERIMENTAL HEMATOLOGY, 2022, 111 : S118 - S118
  • [26] Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
    Bollino, Dominique
    Webb, Tonya J.
    TRANSLATIONAL RESEARCH, 2017, 187 : 32 - 43
  • [27] Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis
    Imeri, Jusuf
    Marcoux, Paul
    Huyghe, Matthias
    Desterke, Christophe
    Fantacini, Daianne
    Griscelli, Frank
    Covas, Dimas T.
    Botelho de Souza, Lucas Edouardo
    Griscelli, Annelise Bennaceur
    Turhan, Ali
    BLOOD, 2023, 142
  • [28] Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
    Thangaraj, Jaya Lakshmi
    Kaufman, Dan S.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2025, (216):
  • [29] DUAL TARGETING STRATEGY OF ACUTE MYELOID LEUKEMIA BY ENGINEERED CYTOKINE-INDUCED KILLER CELLS COEXPRESSING AN INTERLEUKIN 3 CHIMERIC ANTIGEN RECEPTOR (CAR) AND AN ANTI-CD33 COSTIMULATORY RECEPTOR
    Perriello, V.
    Rotiroti, M. C.
    Alberti, G.
    Martelli, M. P.
    Falini, B.
    Tettamanti, S.
    Biondi, A.
    HAEMATOLOGICA, 2020, 105 : S20 - S20
  • [30] TIM-3 Is a Promising Target to Eradicate Acute Myeloid Leukemia Stem Cells Sparing Normal Hematopoietic Stem Cells
    Miyamoto, Toshihiro
    Kikushige, Yoshikane
    Shima, Takahiro
    Akashi, Koichi
    BLOOD, 2011, 118 (21) : 257 - 257